DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

DIGITAL CONTENT

1 NEWS #PharmaBuzz

media
1 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

3DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Ve-822, 1232416-25-9, Vx-970, Ve822, Vx970, Ve 822

Molecular Formula

C₂₄H₂₅N₅O₃S

Molecular Weight

463.6 g/mol

InChI Key

JZCWLJDSIRUGIN-UHFFFAOYSA-N

FDA UNII

L423PRV3V3

Berzosertib is an inhibitor of ataxia telangiectasia and rad3-related (ATR) kinase, a DNA damage response kinase, with potential antineoplastic activity. Upon administration, berzosertib selectively binds to and inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress.

1 2D Structure

Berzosertib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-[3-[4-(methylaminomethyl)phenyl]-1,2-oxazol-5-yl]-5-(4-propan-2-ylsulfonylphenyl)pyrazin-2-amine

2.1.2 InChI

InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)

2.1.3 InChI Key

JZCWLJDSIRUGIN-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)S(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C3=CC(=NO3)C4=CC=C(C=C4)CNC)N

2.2 Other Identifiers

2.2.1 UNII

L423PRV3V3

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-pyrazinamine, 3-(3-(4-((methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-

2. 3-(3-(4-((methylamino)methyl)phenyl)-1,2-oxazol-5-yl)-5-(4-(propane-2-sulfonyl)phenyl)pyrazin-2-amine

3. Ve-822

4. Vx-970

2.3.2 Depositor-Supplied Synonyms

1. Ve-822

2. 1232416-25-9

3. Vx-970

4. Ve822

5. Vx970

6. Ve 822

7. Berzosertib [usan]

8. Ve-822 (vx-970)

9. L423prv3v3

10. M6620

11. 2-pyrazinamine, 3-(3-(4-((methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-

12. 3-(3-{4-[(methylamino)methyl]phenyl}-1,2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phenyl]pyrazin-2-amine

13. 3-[3-[4-(methylaminomethyl)phenyl]-1,2-oxazol-5-yl]-5-(4-propan-2-ylsulfonylphenyl)pyrazin-2-amine

14. 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine

15. M-6620

16. 3-(3-(4-((methylamino)methyl)phenyl)-1,2-oxazol-5-yl)-5-(4-(propane-2-sulfonyl)phenyl)pyrazin-2-amine

17. Bdbm50226746

18. 2-pyrazinamine, 3-[3-[4-[(methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-

19. 3-[3-[4-[(methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-2-pyrazinamine

20. 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine.

21. Unii-l423prv3v3

22. 3-(3-(4-((methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-2-pyrazinamine

23. Vx-970;berzosertib

24. Berzosertib [inn]

25. Berzosertib (usan/inn)

26. Berzosertib (ve-822)

27. Agn-pc-0cxkb3

28. Berzosertib [who-dd]

29. Gtpl8003

30. Schembl3061890

31. Chembl3989870

32. Ex-a529

33. Chebi:131166

34. Bdbm350085

35. Dtxsid601025940

36. Hms3653c05

37. Hms3747i11

38. Bcp07948

39. Mfcd27976794

40. Nsc777718

41. S7102

42. Us10208027, Compound Ii-1

43. Us10208027, Compound Ii-2

44. Us10208027, Compound Ii-3

45. Us10208027, Compound Ii-4

46. Vx 970

47. Zinc96170459

48. Akos025404905

49. Ccg-264673

50. Cs-1861

51. Db11794

52. Nsc-777718

53. Sb17265

54. Ncgc00386313-07

55. Ac-32951

56. As-17041

57. Da-46989

58. Hy-13902

59. Ft-0700136

60. Sw220202-1

61. A13289

62. D11148

63. A857986

64. Q27089129

65. 5-(4-isopropylsulfonylphenyl)-3-[3-[4-(methylaminomethyl)phenyl]isoxazol-5-yl]pyrazin-2-amine

66. Synthesis Of 3-[3-[4-[dideuterio(methylamino)methyl]phenyl]isoxazol-5-yl]-5-(4-isopropylsulfonylphenyl)pyrazin-2-amine

2.4 Create Date

2012-08-20

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₅N₅O₃S
Molecular Weight	463.6 g/mol
XLogP3	2.3
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	7
Exact Mass	463.16781085 g/mol
Monoisotopic Mass	463.16781085 g/mol
Topological Polar Surface Area	132 Å²
Heavy Atom Count	33
Formal Charge	0
Complexity	714
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1